Beware fake flu treatments, FDA warns

(HealthDay)—With the height of flu season here, the U.S Food and Drug Administration warns consumers to avoid fraudulent products that claim to prevent, treat or cure the flu.

Diseases, Conditions, Syndromes

Flu data used to determine vaccine effectiveness

(Medical Xpress)—Armed with data on vaccine effectiveness from five study monitoring sites, including one at the University of Michigan School of Public Health, the Centers for Disease Control is renewing the call for everyone ...

Diseases, Conditions, Syndromes

CDC: Influenza activity increasing across the U.S.

(HealthDay)—Flu season descended on the United States early and hard this winter, with significant increases in flu activity observed over the past month, according to an update issued Jan. 4 by the U.S. Centers for Disease ...


Continuing uncertainties surround anti-influenza drug

Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages ...

page 1 from 3


Zanamivir (INN) (pronounced /zəˈnæmɨvɪr/) is a neuraminidase inhibitor used in the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza.

This text uses material from Wikipedia, licensed under CC BY-SA